Methods for reducing cd36 expression

US2017305967A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2017305967-A1
Application numberUS-201615369281-A
CountryUS
Kind codeA1
Filing dateDec 5, 2016
Priority dateSep 16, 2005
Publication dateOct 26, 2017
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) wherein 3 p m is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p t ) wherein 2a is the largest number that is less than or equal to p t +1, except that when a is 1, p t may also be 1.

First claim

Opening claim text (preview).

1 .- 10 . (canceled) 11 . A method for treating cerebral ischemia in a subject in need thereof, the method comprising administering to the subject an effective amount of an aromatic-cationic peptide or pharmaceutically acceptable salt thereof selected from the group consisting of D-Arg-2′6′Dmt-Lys-Phe-NH 2 and Phe-D-Arg-Phe-Lys-NH 2 . 12 . The method of claim 11 , wherein the peptide is D-Arg-2′6′Dmt-Lys-Phe-NH 2 . 13 . The method of claim 11 , wherein the peptide is Phe-D-Arg-Phe-Lys-NH 2 . 14 . The method of claim 11 , wherein the subject is a human. 15 . The method of claim 11 , wherein the peptide is administered orally, topically, systemically, intravenously, subcutaneously, intramuscularly, intracerebroventricularly, intrathecally, or transdermally.

Assignees

Inventors

Classifications

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • for hyperglycaemia, e.g. antidiabetics · CPC title

  • Drugs for disorders of the cardiovascular system · CPC title

  • for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

  • Antihyperlipidemics · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2017305967A1 cover?
The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p m ) an…
Who is the assignee on this patent?
Cornell Res Foundation Inc
What technology area does this patent fall under?
Primary CPC classification A61K38/07. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Thu Oct 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).